BCL2 and B-cell chronic lymphocytic leukemia: Interestingly, an additional synergistic reduction in CLL survival was detected in an overnight incubation when macitentan was used in combination to 0.001μM BCL2 inhibitor ABT-199 as compared to ABT-199 alone (Figure 3D).